Expression of pepsinogen II with androgen and estrogen receptors in human prostate carcinoma

The expression of pepsinogen II (PG II), an aspartyl proteinase usually involved in the digestion of proteins in the stomach, was immunohistochemically investigated in conjunction with androgen (AR) and estrogen receptor (ER) status in prostate adenocarcinomas. Of a total of 38 samples obtained from radical prostatectomies, 23 tumors (60.5%) were positive for PG II and there was a significant positive correlation to the expression of AR but not to ER. Cells positive for PG II were localized mainly to the peripheral zones of tumorous glands which, in normal prostate, are negative, and in areas also expressing AR. In addition, a significant correlation between AR and ER was detected in the prostate carcinomas examined, which suggests a hormone‐dependent status. On the basis of these results, PG II expression might be closely related to hormonal alterations associated with the development of prostate tumors.

[1]  C. López-Otín,et al.  Hormonal Regulation of the Human Pepsinogen C Gene in Breast Cancer Cells , 1996, The Journal of Biological Chemistry.

[2]  N. Konishi,et al.  Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. , 1995, The American journal of pathology.

[3]  N. Konishi,et al.  Tissue and serum pepsinogen I and II in gastric cancer identified using immunohistochemistry and rapid ELISA. , 1995, Journal of clinical pathology.

[4]  M. Tatematsu,et al.  Glucocorticoids inhibit the proliferation of mucosal cells and enhance the expression of a gene for pepsinogen and other markers of differentiation in the stomach mucosa of the adult rat. , 1994, Biochemical and biophysical research communications.

[5]  R. Zappatore,et al.  Cervical adenocarcinomas express markers common to gastric, intestinal, and pancreatobiliary epithelial cells. , 1994, Pathology, research and practice.

[6]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[7]  J. A. Ruizeveld de Winter.  Immunocytochemical localization of androgen receptor with polyclonal antibody in paraffin-embedded human tissues. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[8]  C. López-Otín,et al.  Expression of pepsinogen C in human breast tumours and correlation with clinicopathologic parameters. , 1993, British Journal of Cancer.

[9]  N. Konishi,et al.  Immunohistochemical evaluation of estrogen receptor status in benign prostatic hypertrophy and in prostate carcinoma and the relationship to efficacy of endocrine therapy. , 1993, Oncology.

[10]  D. Tindall,et al.  Androgen induction of a human prostate-specific kallikrein, hKLK2: characterization of an androgen response element in the 5' promoter region of the gene. , 1993, Biochemistry.

[11]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[12]  C. López-Otín,et al.  Isolation and characterization of a pepsin C zymogen produced by human breast tissues. , 1992, The Journal of biological chemistry.

[13]  R. Zappatore,et al.  Ovarian mucinous tumors frequently express markers of gastric, intestinal, and pancreatobiliary epithelial cells , 1992, Cancer.

[14]  D. Tindall,et al.  Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. , 1991, Cancer research.

[15]  T. Stamey,et al.  Microcarcinoma in the prostate: its association with duct-acinar dysplasia. , 1991, Human pathology.

[16]  P. Chambon,et al.  A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas , 1990, Nature.

[17]  Vijay Kumar,et al.  Androgen, estrogen, and progesterone receptor contents and serum hormone profiles in patients with benign hypertrophy and carcinoma of the prostate , 1990, Journal of surgical oncology.

[18]  F. S. French,et al.  Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. , 1990, Cancer research.

[19]  T. Stamey,et al.  Immunohistochemical evidence for impaired cell differentiation in the premalignant phase of prostate carcinogenesis. , 1988, American journal of clinical pathology.

[20]  T. Stamey,et al.  Differential distribution of pepsinogen II between the zones of the human prostate and the seminal vesicle. , 1986, The Journal of urology.

[21]  R. Priore,et al.  A comparison of estrogen and androgen receptor levels in human prostatic tissue from patients with non-metastatic and metastatic carcinoma and benign prostatic hyperplasia. , 1985, Journal of steroid biochemistry.

[22]  W. Liebman,et al.  Purification and immunochemical characterization of group II pepsinogens in human seminal fluid. , 1972, Clinical and experimental immunology.

[23]  N. Konishi,et al.  Different patterns of DNA alterations detected by restriction landmark genomic scanning in heterogeneous prostate carcinomas. , 1997, The American journal of pathology.

[24]  Chawnshang Chang,et al.  Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates , 1990, The Prostate.

[25]  W. Lang.  Vaginal diseases. , 1967, Journal of the American College Health Association.